March 10, 2025

HEIDELBERG UNIVERSITY HOSPITAL AMONG THE WORLD’S BEST HOSPITALS IN 2025

HEIDELBERG UNIVERSITY HOSPITAL AMONG THE WORLD’S BEST HOSPITALS IN 2025
Go back

The US magazine “Newsweek” has once again named Heidelberg University Hospital (UKHD) one of the best hospitals in the world. In the “World’s Best Hospitals 2025” ranking, which is compiled by “Newsweek” in collaboration with the statistics and data platform “Statista”, the UKHD ranks 14th out of 2,400 hospitals worldwide. In Germany, the UKHD is in second place, just behind the Berlin Charité.

The assessment by Newsweek is based on the opinions of healthcare experts, patient surveys and key performance indicators of the evaluated hospitals. The ranking compared hospitals from 30 countries, including Germany, the United States, Canada, England and Switzerland. In total, more than 2,400 hospitals worldwide were included in the comparison.

Worldwide comparison

Germany-wide comparison

Our latest News

discover more
Combating the pandemic: Diagnostic chips ten times more sensitive

Combating the pandemic: Diagnostic chips ten times more sensitive

A team at KIT has developed a solution that significantly improves novel biosensors for medical use and enables faster diagnosis of infectious diseases Rapid, straightforward and, at the same time, accurate diagnosis of highly contagious pathogens such as the SARS-CoV-2 virus, which caused the coronavirus pandemic, is crucial to curbing the spread of disease. This […]

read more
Center of Excellence in Oncology: NCT Heidelberg and Mannheim Cancer Center Receive Joint Funding

Center of Excellence in Oncology: NCT Heidelberg and Mannheim Cancer Center Receive Joint Funding

Joint Press Release from NCT Heidelberg and Mannheim University Medical Center The National Center for Tumor Diseases (NCT) Heidelberg and the Mannheim Cancer Center (MCC) are receiving joint funding as a Center of Excellence in Oncology for the first time. German Cancer Aid is providing 4.8 million euros over four years for the new consortium. […]

read more
Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease

Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease

Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Paris, August 4, 2026. Sanofi today announced that the European Commission (EC) has approved an extension of the indication for MenQuadfi (Meningococcal Group A, C, W and Y conjugate vaccine) to include infants from six weeks of age […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp